Cancer Characterization Equipment
-
Manufactured by TC BioPharmbased in UNITED KINGDOM
is a cancer characterized by infiltration of the bone marrow, blood, and other tissues by proliferative, clonal, poorly differentiated cells of the hematopoietic system and is predicted to affect 22,000 people per year in the ...
-
Manufactured by TC BioPharmbased in UNITED KINGDOM
TCB002 is an unmodified allogeneic gamma delta T cell product, being initially used for the treatment of Acute Myeloid Leukaemia (AML). This product is currently undergoing a phase 1 clinical trial as part of a dose escalation and safety study, in partnership with ÚKHT, Institute of Hematology and Blood Transfusion, Prague. AML is a ...
-
by Debiopharmbased in SWITZERLAND
Oxaliplatin is a diaminocyclohexane (DACH) platin. It is the active substance of the branded Eloxatin®/Elplat®/Dacotin®/Dacplat®, which has dramatically changed the prognosis of colorectal cancer. In 1996, prior to the introduction of oxaliplatin, the standard of care for colorectal cancer was 5-fluorouracil (5-FU). ...
-
Manufactured by Bioceptbased in USA
his kit detects BRAF V600 mutations in DNA derived from blood plasma or FFPE tissue sections to give insight into cancer characteristics and provide Biomarker status of tumors such as ...
-
Manufactured by Cancer Targeted Technologybased in USA
CTT1057 is an innovative 18F-labeled PET agent for prostate cancer that can be imaged within 2 hours of administration. CTT1057 will specifically and sensitively detect cancer that has escaped from the prostate as well as distant metastatic disease including bone metastases with greater precision and resolution than current standard of ...
-
Manufactured by Bioceptbased in USA
This kit detects EGFR mutations in DNA derived from blood plasma or FFPE tissue sections to give insight into cancer characteristics and provide Biomarker status of tumors such as non-small cell lung ...
-
Manufactured by Cancer Targeted Technologybased in USA
CTT’s lead therapeutic product, CTT1403, is a PSMA-targeted 177Lu-labeled agent for prostate cancer that can has superior binding characteristics, long circulation half-life, enhanced tumor uptake and unparalleled anti-tumor efficacy. CTT1403 will specifically deliver the radionuclide, 177Lu, minimizing toxic side effects and ...
-
Manufactured by Amadixbased in SPAIN
PancreaDix is an innovative, non-invasive signature in blood for: Confirming a Pancreatic cancer diagnosis. Detecting pre-malignant lesions that will evolve to cancer. Performing a differential diagnosis between Pancreatic cancer and other pathologies such as chronic pancreatitis or neuroendocrine tumors. ...
-
Manufactured by AC BioScience SAbased in SWITZERLAND
Our medical objective is to validate and bring to clinical use, a novel approach to improve the treatment of metastatic pancreatic adenocarcinoma using a proangiogenic molecule S1P lyase inhibitor acting as a tumor vascular ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you